New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
05:17 EDTKPTIKaryopharm announces first combination data of Selinexor Phase 1 trial
Karyopharm Therapeutics announced initial Phase 1 data from patients with multiple myeloma treated with Karyopharm's lead selective inhibitor of nuclear export, or SINE, Selinexor, in combination with "low-dose" dexamethasone. Among eight patients, the best responses were one stringent complete response, or sCR, three partial responses, or PRs, two minor responses, or MRs, one progressive disease and one non-evaluable. Accordingly, the clinical benefit response rate is 75% and the overall response rate. Adverse events in patients receiving single-agent Selinexor were generally low-grade, consistent with events observed in patients with other hematological malignancies and responsive to standard supportive care. Compared with Selinexor given alone, fewer adverse events in patients receiving Selinexor in combination with dexamethasone were reported, consistent with dexamethasone's reduction in Selinexor's main side effects of nausea, anorexia, and fatigue.
News For KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
08:05 EDTKPTIKaryopharm presents data on oncology pipeline
Karyopharm Therapeutics announced the presentation of data describing its oncology product candidates at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain held November 18-21. Data for its lead product candidate, Selinexor, a first-in-class, oral Selective Inhibitor of Nuclear Export / SINE compound, described its synergistic anti-tumor activity in combination with DNA damage-inducing treatments such as anthracyclines or radiation in a non-small cell lung cancer mouse model. In addition, a description of a newly developed pharmacodynamic assay designed to evaluate direct Selinexor binding to XPO1 in patients was presented. Finally, data describing the identification of novel mechanism PAK4 allosteric modulators and their ability to inhibit tumor cell growth and induce apoptosis were presented. In a poster entitled "Selective Inhibitors of Nuclear Export (SINE™) Block the Expression of DNA Damage Repair Proteins and Sensitize Cancer Cells to DNA Damage Inducing Agents," data demonstrated that Selinexor inhibited the DNA repair mechanisms in solid and hematological cancer cell lines and therefore, preventing the cancer cell recovery following treatment with agents that cause DNA damage, leading to increased cancer cell death.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use